Baseline demographics, disease characteristics and PRO scores of patients in AMBITION and ADACTA
| AMBITION | ADACTA | |||
| Baseline characteristic* | TCZ 8 mg/kg (n=265) | MTX 7.5–20 mg (n=259) | TCZ 8 mg/kg (n=163) | ADA 40 mg (n=162) |
| Age, years | 51.1 (13.1) | 50.1 (12.8) | 54.4 (13.0) | 53.3 (12.4) |
| Female, n (%) | 219 (83) | 211 (81) | 129 (79) | 133 (82) |
| White, n (%) | 187 (71) | 188 (73) | 145 (89) | 133 (82) |
| Disease duration, years | 6.4 (7.7) | 6.3 (7.9) | 7.3 (8.1) | 6.3 (6.9) |
| Number of prior DMARDs | 1.2 (1.3) | 1.1 (1.4) | 2.0 (1.1) | 2.0 (1.1) |
| CDAI | 43.2 (12.9) | 43.2 (11.8) | 40.8 (12.3) | 43.1 (12.6) |
| PtGA, VAS 0–100 mm | 64.0 (21.5) | 65.4 (19.5) | 71.2 (20.8) | 73.4 (19.4) |
| Pain, VAS 0–100 mm | 59.2 (22.5) | 61.3 (20.4) | 67.2 (21.3) | 67.9 (20.7) |
| HAQ-DI, 0–3 | 1.6 (0.7) | 1.5 (0.6) | 1.6 (0.6) | 1.7 (0.6) |
| FACIT-Fatigue, 0–52 | 27.4 (10.6) | 27.8 (10.5) | 24.9 (10.6) | 24.1 (11.2) |
| SF-36 PCS (mean: 50, SD: 10) | 31.9 (7.5) | 31.1 (6.9) | 30.5 (7.9) | 30.2 (7.9) |
| SF-36 MCS (mean: 50, SD: 10) | 40.2 (12.0) | 40.6 (11.3) | 39.7 (12.0) | 38.9 (12.3) |
| SF-36 domains, 0–100 | ||||
| Physical functioning | 37.1 (24.1) | 37.0 (23.2) | 34.4 (22.0) | 32.9 (24.0) |
| Role-physical | 13.6 (26.8) | 13.3 (28.2) | 34.0 (20.9) | 35.4 (24.2) |
| Bodily pain | 29.1 (17.2) | 27.6 (15.2) | 27.2 (19.1) | 24.5 (16.7) |
| General health | 42.1 (19.9) | 40.1 (19.6) | 42.5 (19.4) | 40.6 (18.6) |
| Vitality | 35.7 (19.7) | 37.0 (19.1) | 32.7 (18.1) | 32.8 (19.5) |
| Social functioning | 48.3 (26.4) | 50.2 (24.8) | 48.0 (26.9) | 47.7 (26.8) |
| Role-emotional | 34.9 (41.7) | 32.7 (42.8) | 54.4 (30.7) | 50.3 (31.7) |
| Mental health | 55.5 (22.0) | 57.7 (20.3) | 54.9 (19.5) | 54.1 (20.9) |
*All values are presented as mean (SD) unless otherwise indicated.
ADA, adalimumab; CDAI, Clinical Disease Activity Index; DMARDs, disease-modifying antirheumatic drugs; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire Disability Index; MCS, mental component summary; MTX, methotrexate; PCS, physical component summary; PRO, patient-reported outcome; PtGA, patient global assessment; SF-36, Short Form-36; TCZ, tocilizumab; VAS, visual analogue scale.